Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comfort Systems USA Inc (FIX) vs Heron Therapeutics Inc (HRTX) Price & Performance

Comfort Systems USA IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Comfort Systems USA Inc vs Heron Therapeutics Inc — how do they compare? Comfort Systems USA Inc trades at $1,686 (market cap $58.94B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Comfort Systems USA Inc is far larger — about 929.5× Heron Therapeutics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

FIXHRTX
Market Cap
$58.94B$63.41M
Sector
TechnologyHealth
52-Week High
$2.07K$1.49
52-Week Low
$680.86$0.33
Enterprise Value
$57.42B$161.31M
Dividend Yield
0.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comfort Systems USA Inc

FIX trades at $1,694.55, down 1.11% today, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating estimates with EPS of $12.53 versus $10.45 expected, driven by robust data center demand. Revenue grew to $11.2B in 2026, with net profit margin expanding to 12.77%. Analyst consensus is bullish with a $2,170 price target, though valuation multiples like P/E of 41.22 appear elevated.

Outlook remains positive given record backlog and AI-driven demand, but risks include high execution demands and premium valuation. The stock offers growth exposure to the construction and data center sectors, supported by institutional interest and consistent dividend payments, though investors should monitor capacity constraints and competitive pressures.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Comfort Systems USA Inc

Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.

Read more on FIX

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX